Digital Biotechnologies, a Seattle-based spinout from Adaptive Biotechnologies, has secured $15M in a Series A funding round. The company focuses on DNA sequencing technology for clinical applications, complementing Adaptive’s work in immune medicine and minimal residual disease (MRD) testing. This funding supports the development of next-generation sequencing solutions for healthcare diagnostics.
Digital Biotechnologies Inc., a Seattle-based spinout from Adaptive Biotechnologies, secures a $15 million Series A round to develop a clinical DNA sequencing instrument. The funding supports early-stage research and instrument design for potential medical diagnostics applications. The company aims to leverage Adaptive’s expertise in immunosequencing to advance precision medicine tools.
Adaptive Biotechnologies’ subsidiary **Digital Biotechnologies** secures **$15 million in Series A financing** for clinical sequencing applications. The round includes an initial closing of preferred stock, with plans to expand the total raise. The funding supports the subsidiary’s focus on advancing sequencing technologies for clinical diagnostics.
Digital Biotechnologies, an Adaptive Biotechnologies subsidiary, secures Series A funding to advance a clinical-grade DNA sequencing device. The Seattle-based company focuses on scaling sequencing technology for medical diagnostics. Development targets integration with clinical workflows and regulatory compliance.
Adaptive Biotechnologies’ 70%-owned subsidiary, Digital Biotechnologies, secures up to $15 million in a Series A financing round. The funds follow an initial closing of the preferred stock offering. The company focuses on digital biology applications, though specific use cases were not detailed in the announcement.